miR-125b and miR-532-3p predict the efficiency of rituximab-mediated lymphodepletion in chronic lymphocytic leukemia patients. A French Innovative Leukemia Organization study.

doi:10.3324/haematol.2016.153189

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

miR-125b and miR-532-3p predict the efficiency of rituximab-mediated lymphodepletion in chronic lymphocytic leukemia patients. A French Innovative Leukemia Organization study.

Haematologica - 1 Apr 2017

Gagez Anne-Laure, Duroux-Richard Isabelle, Leprêtre Stéphane, Orsini-Piocelle Frédérique, Letestu Rémi, De Guibert Sophie, Tuaillon Edouard, Leblond Véronique, Khalifa Olfa, Gouilleux-Gruart Valérie, Banos Anne, Tournilhac Olivier, Dupuis Jehan, Jorgensen Christian, Cartron Guillaume, Apparailly Florence

Abstract excerpt

The underlying in vivo mechanisms of rituximab action remain incompletely understood in chronic lymphocytic leukemia. Recent data suggest that circulating micro-ribonucleic acids correlate with chronic lymphocytic leukemia progression and response to rituximab. Our study aimed at identifying circulating micro-ribonucleic acids that predict response to rituximab monotherapy in chronic lymphocytic leukemia...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Combined Chemotherapy Protocols

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Diagnosis, Differential

Share to Gene Expression Regulation, Leukemic

Share to Leukemia, Lymphocytic, Chronic, B-Cell

Share to Lymphocyte Depletion

Share to Lymphocytosis

Share to Rituximab

Share to RNA Interference

Source

Open in PubMed Open full text

Identifiers

PMID: 28126961
DOI: 10.3324/haematol.2016.153189
PMCID: PMC5395115

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 10 closest

miR-125b and miR-532-3p predict the efficiency of rituximab-mediated lymphodepletion in chronic lymphocytic leukemia patients. A French Innovative Leukemia Organization study.PMID 28126961Read ↗

Plasma microRNA profiling: Exploring better biomarkers for lymphoma surveillanceSemantic proximity Read ↗

miR-125a and miR-34a expression predicts Richter syndrome in chronic lymphocytic leukemia patientsSemantic proximity Read ↗

Alternative splicing of its 5′-UTR limits CD20 mRNA translation and enables resistance to CD20-directed immunotherapiesSemantic proximity Read ↗

MicroRNA microarrays on archive bone marrow core biopsies of leukemias—Method validationSemantic proximity Read ↗

MicroRNA Expression, Chromosomal Alterations, and Immunoglobulin Variable Heavy Chain Hypermutations in Mantle Cell LymphomasSemantic proximity Read ↗

Alternative splicing of its 5’-UTR limits CD20 mRNA translation and enables resistance to CD20-directed immunotherapiesSemantic proximity Read ↗

Quantitative technologies establish a novel microRNA profile of chronic lymphocytic leukemiaSemantic proximity Read ↗

MicroRNA profiling reveals distinct signatures in B cell chronic lymphocytic leukemias.Semantic proximity Read ↗

microRNA expression in the biology, prognosis, and therapy of Waldenström macroglobulinemiaSemantic proximity Read ↗

A Plasmablast Biomarker for Nonresponse to Antibody Therapy to CD20 in Rheumatoid ArthritisSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.